Novartis investigational lung cancer therapy grabs breakthrough status

The U.S. FDA has granted Breakthrough Therapy designation to Novartis'capmatinib, which the drugmaker aims to file for approval later this year to treat a mutated form of lung cancer.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news

Related Links:

Li Naturally occurring polyphenols are believed to have beneficial effects in the prevention and treatment of a myriad of disorders due to their anti-inflammatory, antioxidant, antineoplastic, cytotoxic, and immunomodulatory activities documented in a large body of literature. In the era of molecular medicine and targeted therapy, there is a growing interest in characterizing the molecular mechanisms by which polyphenol compounds interact with multiple protein targets and signaling pathways that regulate key cellular processes under both normal and pathological conditions. Numerous studies suggest that natural poly...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
With the popularization of Next-generation sequencing technology, targeted cancer therapy based on gene mutations has attracted more and more attention. Aberrant activated mitogen-activated protein kinases (MAPK) pathway is considered to play a crucial role in the occurrence and development of various cancers [1]. Various mutations in pathway components including MEK1/2 can cause the aberrant activation of MAPK signaling pathway [2]. As oncogenic mutations, MEK1 mutations were widely observed in many cancers [1,3,4], while trametinib, a MEK1/2 inhibitor, was limited to treat BRAF-mutant melanoma and non-small-cell lung can...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research
We present a case of fulminant diabetes after only two cycles of pembrolizumab in a 53-year-old man with a history of metastatic lung cancer who presented to our emergency department with coma and acidosis revealing diabetic ketoacidosis.
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Source Type: research
Dr Suresh Ramalingam discusses the findings presented at two recent meetings that offer new treatment options for patients with lung cancer.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Abstract The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodies have been approved for use in advanced solid tumors, including melanoma, non-small cell lung cancer (NSCLC), bladder cancer, and other cancers. ICIs are under development across many tumor types and preliminary results are compelling. However, ICIs have been associated with severe immune-related adverse event...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Publication date: Available online 3 October 2019Source: Colloids and Surfaces A: Physicochemical and Engineering AspectsAuthor(s): Chuanmin Zhang, Shubiao Zhang, Defu Zhi, Yinan Zhao, Shaohui Cui, Jingnan CuiAbstractThis work designed a new delivery system (L-PTX-PSur), which could efficiently co-deliver paclitaxel (PTX) and survivin siRNA (Sur) to overcome the dose-limiting toxicity by effectively accumulating PTX in tumor and obtain enhanced therapy by synergistic effect. In this co-delivery system, protamine was selected to condense siRNA into a compacted ‘core’, and a carbamate-linked cationic lipid was us...
Source: Colloids and Surfaces A: Physicochemical and Engineering Aspects - Category: Chemistry Source Type: research
Lung carcinoma therapy using epidermal growth factor receptor‑targeted lipid polymeric nanoparticles co‑loaded with cisplatin and doxorubicin. Oncol Rep. 2019 Sep 18;: Authors: Nan Y Abstract The rate of lung cancer in tuberculosis (TB) patients is 7 to 30% higher than that in healthy individuals. Conventional chemotherapy of lung cancer shows limited efficiency due to poor tumor tissue drug accumulation and nonspecific cytotoxicity. Epidermal growth factor receptor (EGFR) is a promising target, which is overexpressed in lung carcinomas. In the present study, EGFR‑targeted nanopart...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Ichihara E, Miyahara N, Maeda Y, Kiura K Abstract Systemic therapy for advanced non-small cell lung cancer (NSCLC) has dramatically changed in the latest 15 years. Molecular-targeted therapy has brought about an era of precision medicine, and immune checkpoint inhibitors have brought hope for a cure for advanced NSCLC. In the wake of this remarkable advancement, lung cancer with comorbid interstitial pneumonia (IP) has been completely left behind, as most clinical trials exclude patients with comorbid IP. IP, especially idiopathic pulmonary fibrosis (IPF), is often accompanied by lung cancer, and acute exa...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
ConclusionsTreatment with GOLPH2-directed antibodies induces durable responses in colorectal and lung cancer models. With a robust companion assay for GOLPH2 positivity at hand our findings prepare for the translation into a clinical trial.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Abstract Lung cancer, similar to other chronic diseases, occurs due to perturbations in multiple signaling pathways. Mono-targeted therapies are not ideal since they are not likely to be effective for the treatment and prevention of lung cancer, and are often associated with drug resistance. Therefore, the development of multi-targeted agents is required for novel lung cancer therapies. Thioredoxin reductase (TrxR or TXNRD1) is a pivotal component of the thioredoxin (Trx) system. Various types of tumor cells are able to overexpress TrxR/Trx proteins in order to maintain tumor survival, and this overexpression has ...
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Lung Cancer | Pharmaceuticals